Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance
Christos Damaskos, Nikolaos Garmpis, Nikolaos Arkadopoulos, Nikolaos V. Michalopoulos, Anna Garmpi, Miltiadis-Panagiotis Papandroudis, Eleni I. Effraimidou · 2026
Read Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance by Christos Damaskos, Nikolaos Garmpis, Nikolaos Arkadopoulos, Nikolaos V. Michalopoulos, Anna Garmpi, Miltiadis-Panagiotis Papandroudis, Eleni I. Effraimidou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13207011.txt.
Description
Christos Damaskos and co-authors review capivasertib for breast cancer in a 2026 paper. The drug blocks AKT, a signal hub that helps hormone-driven tumors resist standard therapy. It is approved with fulvestrant for set tumor types. Pathway faults mark the patients most likely to gain.
The review sums trials from early to late phase. The combo lengthened time without progression in advanced disease. Gains ran largest in tumors with faults in one of three pathway genes. Combos with a chemo drug or a DNA repair blocker showed added effects in other breast types. Biomarkers and resistance paths are charted for future work.
Catalog record
| CREATOR | Christos Damaskos, Nikolaos Garmpis, Nikolaos Arkadopoulos, Nikolaos V. Michalopoulos, Anna Garmpi, Miltiadis-Panagiotis Papandroudis, Eleni I. Effraimidou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |